1Estelle F, Simons R. H1-receptor antagonists: safety issues[J]. Ann Allergy Asthma Immunol, 1999, 83(5):481 -488.
2Ten Eick AP, Blumer JL, Reed MD. Safety of antihistamines in children[J]. Drug Saf, 2001,24(2): 119 -147.
3Woosley RL. Cardiac actions of antihistamines[J]. Annu Rev Pharmacol Toxicol, 1996, 36:233-252.
4Frieri M. Treatment update for allergic rhinitis[J]. Allergy Asthma Proc, 2000, 21(6):377-379.
5Horak F, Stubner P,Zieglmayer R, et al. Controlled compaison of the efficacy and safety of cetirizine 10 mg o.d.and fexofenadine 120 mg o.d. in reducing symptoms of seasonal allergic rhinitis[J]. Int Arch Allergy Immunol, 2001,125(1) :73 - 79.
6Kaliner MA. H1- antihistamines in the elderly[J]. Clin Allergy Immunol, 2002,17:465 - 481.
7Simpson K, Jarvis B. Fexiffenadine: a review ff its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria[J]. Drugs, 2000, 59(2) :301 - 321.
8Amichai B, Grunwald MH, Brenner L. Fexffenadine hydrochloride - a new anti-histaminic drug[J]. Isr Med Assoc J, 2001,3(3):207-209.
9Benedetto SR, Sloan AS, Duncan BS. Impact of interventions designed to increase market share and prescribing of fexofenadine at HMOs[J]. Am J Health Syst Pharm, 2000,57(19): 1778 - 1785.
10Craig-McFeely PM, Freemantle SL, Pearce GL, et al. QT lengthening and life-threatening arrhythmias associated with fexofenadine[J]. Br J Gen Pract, 2000, 50(451): 148.
